强直性脊柱炎患者既往暴露于TNF抑制剂后司库奇尤单抗与TNF抑制剂转换的留存率与有效性比较
该研究基于韩国风湿病学会BIOlogics注册队列,纳入既往暴露于TNF抑制剂(TNFi)的强直性脊柱炎(AS)患者,比较转换为司库奇尤单抗与转换为另一种TNFi的药物留存率和临床疗效。随访1年数据显示,两组在药物停用风险及BASDAI50、ASAS20/40、ASDAS<2.1等疗效指标上均无显著差异,提示两种转换策略效果相当。
要点
- 既往TNFi暴露的AS患者转换为司库奇尤单抗或另一种TNFi,1年药物留存率相当。
- 两组BASDAI50、ASAS20/40、ASDAS<2.1等疗效指标均无显著差异。
- 因无效停用TNFi的亚组中,两组所有临床疗效参数同样相当。
核心结论
- 在既往暴露于TNFi的AS患者中,转换为司库奇尤单抗与转换为另一种TNFi在药物留存和临床疗效方面结果相当。
研究设计与样本
- 基于韩国风湿病学会BIOlogics注册队列的观察性研究,排除非放射学轴性脊柱关节炎患者。
- 既往TNFi暴露的AS患者分为司库奇尤单抗组和TNFi转换组,随访1年评估药物留存和临床疗效。
主要发现
- 司库奇尤单抗作为第三线或更后线生物制剂的比例高于替代TNFi(54% vs 14%)。
- 倾向评分匹配和多重协变量校正分析显示,司库奇尤单抗组与TNFi转换组的药物停用风险相当[OR 1.136(95% CI 0.843, 1.531)和1.000(95% CI 0.433-2.308)]。
- 倾向评分匹配分析中,两组达到BASDAI50的比例相当[OR 0.833(95% CI 0.481, 1.441)]。
- 其他临床疗效参数在两组间也相当。
- 在因无效停用TNFi的AS患者亚组分析中,两组所有临床疗效参数均相当。
关键数值与推荐
- 药物停用风险的OR在司库奇尤单抗组为1.136(95% CI 0.843, 1.531),TNFi转换组为1.000(95% CI 0.433-2.308)。
- BASDAI50的OR在倾向评分匹配分析中为0.833(95% CI 0.481, 1.441)。
临床怎么用
- 对于既往暴露于TNFi的AS患者,转换为司库奇尤单抗或另一种TNFi均可作为合理选择,两者1年留存和疗效相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The choice of second-line biologics for AS patients previously treated with a TNF inhibitor (TNFi) remains unclear. Here, we compared drug retention and clinical efficacy between AS patients who switched biologics to secukinumab and those who switched to a different TNFi. METHODS: AS patients enrolled in the Korean College of Rheumatology BIOlogics registry were included, and patients with non-radiographic axial spondyloarthritis were excluded. Patients with previous TNFi exposure were divided into the secukinumab group and the TNFi switching group. Drug retention and clinical efficacy [BASDAI50, Assessment of Spondylo-Arthritis International Society (ASAS)20, ASAS40, AS disease activity score (ASDAS) <2.1, ASDAS clinically important improvement and ASDAS major improvement] were assessed at the 1 year follow-up. Propensity score (PS)-matched and covariate-adjusted logistic regression analyses were performed. RESULTS: Two hundred and forty-six had available 1 year follow-up data. Secukinumab as third- or later-line biologic was more frequent than alternative TNFi (54% vs 14%). PS-matched and multiple covariate-adjusted analyses showed that the odds ratio (OR) for drug discontinuation was comparable between the secukinumab and TNFi switching groups [OR 1.136 (95% CI 0.843, 1.531) and 1.000 (95% CI 0.433-2.308), respectively]. The proportion of patients who achieved BASDAI50 was also comparable between the two groups [OR 0.833 (95% CI 0.481, 1.441) in PS-matched analysis]. Other clinical efficacy parameters were also comparable. In the subgroup analysis of AS patients with previous TNFi discontinuation due to ineffectiveness, all clinical efficacy parameters were comparable between the two groups. CONCLUSION: In AS patients with previous exposure to a TNFi, switching biologics to secukinumab and switching to an alternative TNFi resulted in comparable drug retention and clinical efficacy.
引用
- Min HK, Kim HR, Lee SH, et al. Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure. Rheumatology (Oxford). 2021. PMID: 33725088. doi:10.1093/rheumatology/keab245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。